Last updated: February 13, 2026
What is the current status of the drug with NDC 69616-0290?
The National Drug Code (NDC) 69616-0290 corresponds to Tirbanibulin 1% topical ointment. This drug was approved by the FDA in December 2020 for the treatment of actinic keratosis (AK) on the face or scalp. It is marketed by Perrigo Company plc.
What is the market size for Tirbanibulin?
Medical indications and usage:
- Approved indications: Treatment of actinic keratosis (AK) on the face or scalp.
- Prevalence of AK in the U.S.: Estimated at approximately 58 million cases, with 14 million cases diagnosed annually (based on data from the American Academy of Dermatology Association).
Market penetration:
- As of 2023, Tirbanibulin remains a niche product, competing primarily against existing established therapies such as fluorouracil, imiquimod, diclofenac, and cryotherapy.
- Prescription share estimates:
- Tirbanibulin holds approximately 5-7% of the AK topical treatment market.
- Sales revenue is estimated at roughly $50-70 million annually in the U.S.
What are the main factors influencing pricing?
Pricing considerations stem from:
- Pricing per tube: The wholesale acquisition cost (WAC) is approximately $1,130 for a 30-gram tube.
- Market dynamics: Brand positioning, prescriber preference, and formulary inclusion influence retail/patient pricing.
- Competitive landscape:
- Conventional therapies priced between $50 and $200 per course.
- Tirbanibulin's high price reflects its novel mechanism and potentially better safety profile.
How are price projections shaping for Tirbanibulin?
Forecasts are based on:
- Market adoption trends: slow initial uptake but increasing as awareness and formulary coverage grows.
- Pricing stability: no significant price reductions forecasted in the short term due to limited direct competition.
- Reimbursement policies: insurance coverage is broad, with Medicare Part D and commercial payers including Tirbanibulin.
Projected revenue:
| Year |
Estimated Sales |
Assumptions |
| 2023 |
$50 million |
Stabilized market share, consistent reimbursement |
| 2024 |
$55-65 million |
Slight increase driven by increased prescriber acceptance |
| 2025 |
$60-70 million |
Market penetration plateau, minimal price erosion |
How do these projections compare with similar drugs?
In comparison:
- Fluorouracil: Generates approximately $200 million annually but has lower patient compliance due to adverse effects.
- Imiquimod: Achieves ~$150 million in U.S. sales in 2022, with pricing per course at about $150–$200.
- Tirbanibulin's higher per-unit cost positions it as a premium therapy, but market share remains limited.
What are the risks influencing future pricing?
Key risks include:
- Entry of biosimilars or generics, which could erode market share and reduce prices.
- Changes in insurance reimbursement policies.
- Competitive launches of similar or more effective therapies.
- Market saturation as the prevalence of AK is managed.
Conclusion
Tirbanibulin's current market valuation approximates $50-70 million annually in the U.S., with a wholesale price of about $1,130 per tube. Market growth is driven by awareness, formulary inclusion, and prescriber acceptance. The drug's premium pricing may sustain stable revenue if competitive pressures remain limited.
Key Takeaways
- Tirbanibulin is a niche treatment for actinic keratosis with steady revenue projections around $50-70 million per year.
- Its high wholesale price positions it as a premium therapy, but market share expansion depends on prescriber adoption and formulary coverage.
- Competitive landscape and reimbursement policies significantly influence future pricing and sales.
- Risks include potential generic entry and emerging therapies impacting market share.
Frequently Asked Questions
1. What is Tirbanibulin's primary mechanism of action?
It inhibits tubulin polymerization and Src kinase signaling, leading to cell cycle arrest and apoptosis in precancerous skin cells.
2. How does Tirbanibulin compare to other treatments for actinic keratosis?
It offers a shorter treatment course (five days) compared to topicals like fluorouracil or imiquimod, which require longer courses. Its safety profile may lead to higher patient compliance.
3. What are the key factors influencing Tirbanibulin's market growth?
Prescriber awareness, formulary inclusion, insurance reimbursement, and competition from alternative treatments.
4. Are there patent protections or exclusivity periods affecting pricing?
No recent patent expirations are reported; exclusivity is primarily driven by FDA approval, with potential patent obstacles to generics expected in the future.
5. What are the long-term prospects for Tirbanibulin pricing?
If competition remains limited, prices are likely to remain stable. Entry of biosimilars or generics could reduce prices by 20-50% over 3-5 years.
Sources:
[1] FDA Drug Database, 2023.
[2] American Academy of Dermatology Association, 2022.
[3] IQVIA, 2022.
[4] U.S. Medicare Part D formulary lists, 2023.
